AUS
NZ
UK
CA
USA
IND
Highlights
- Pro Medicus reported significant profit growth with solid financial health.
- The company’s radiology IT software and Visage platform play a key role in the healthcare sector.
- PME has a strong return on equity and minimal debt, positioning it well for future performance.
Pro Medicus Limited, a leading provider of radiology IT software, has seen a significant rise in its share price throughout 2024. With a strong foothold in the healthcare sector, Pro Medicus offers key software solutions, including radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation technologies. These solutions help hospitals and imaging centers manage everything from patient scheduling to detailed medical imaging analysis. At the core of the ASX healthcare stock’s offerings is its flagship Visage software, enabling radiologists to access and interpret large image files, enhancing efficiency and patient outcomes.
Key Financial Metrics for Pro Medicus (ASX:PME)
When assessing the financial health and performance of Pro Medicus, several critical metrics stand out. Revenue, gross margin, and profit offer insights into the company’s trajectory and potential for growth.
- Revenue: Revenue forms the foundation of any company’s financial performance. Pro Medicus reported a revenue of $162 million in its latest annual report, showing a compound annual growth rate (CAGR) of 33.4% over the last three years. This reflects the company’s ability to consistently grow its income, driven by its expanding global presence and innovative software solutions.
- Gross Margin: A strong gross margin is vital for understanding profitability before overhead costs are considered. Pro Medicus boasts an impressive gross margin of 99.8%, highlighting the profitability of its core products. This high percentage underscores the value the company’s technology brings to its clients.
- Profit: In the most recent financial year, Pro Medicus reported a profit of $83 million, a substantial increase from $31 million three years ago. This represents a CAGR of 39.0%, demonstrating the company’s consistent profit growth. Such upward momentum positions Pro Medicus as a notable performer in the healthcare technology sector.
Capital Health and Stability
Another critical aspect of evaluating Pro Medicus is its capital structure and financial health. A key indicator is the company’s net debt, which currently sits at -$153 million. This negative value means the company has more cash than debt, placing it in a strong position to manage operational costs without significant financial strain.
Additionally, the debt-to-equity ratio of Pro Medicus is a low 1.1%, indicating minimal leverage and a conservative approach to debt management. This reflects the company’s robust capital health, allowing it to navigate market uncertainties with greater stability.
Finally, Pro Medicus has a return on equity (ROE) of 50.7%, signaling a high level of profitability relative to its total equity. This metric shows the company’s ability to efficiently generate profits from its shareholder capital, adding to its overall financial strength.
With its advanced software solutions, impressive financial performance, and strong capital health, Pro Medicus continues to be a company to monitor closely in the healthcare IT sector. The combination of rising revenue, growing profits, minimal debt, and a strong ROE solidifies its position as a key player with substantial growth potential in the years to come.
